Bone-marrow derived MSCs may reduce acute rejection rates in kidney recipients News-Medical.net "Antibody-based induction therapy plus calcineurin inhibitors (CNIs) reduce acute rejection rates in kidney recipients; however, opportunistic infections and toxic CNI effects remain challenging. Reportedly, mesenchymal stem cells (MSCs) have ... DRI Study Shows Stem Cells Can Replace Anti-Rejection Drug for Transplants |
